The Global Alzheimer’s Crisis: New Paradigms in Clinical Trials and Longitudinal Screening
Professor Alan Palmer FRSB PhD, MSc, BSc, Board Director of The Brain Tumour Charity
Kathryn M. Martin, M.A., Manager of Patient Recruitment Strategy, Acurian
There is scientific knowledge. And there is public perception. And often, the two collide. Nowhere is this reality more explicit than with the current state of Alzheimer’s disease research. Without a definitive cause or diagnosis – and no cure in sight – many adults see no reason to assess their risk, or determine their cognitive status, if little can be done to stave off the disease. These perceptions present a growing challenge to clinical trial enrollment and Alzheimer’s research overall.
Acurian’s webinar will explore the:
- Current status of global Alzheimer’s disease research
- Patient and caregiver perceptions and motivations that influence clinical trial participation
- Barriers to enrolling patients in clinical trials and strategies to overcome these barriers
- Benefits of online self-assessments and longitudinal screening
Join us to learn about innovative methods to enrolling Alzheimer’s clinical trials and advancing research for this global health crisis.
About the Sponsors
Founded in 1998, Acurian, a subsidiary of PPD, is a leading full-service provider of patient enrollment and retention solutions for the life sciences industry. The company increases the enrollment performance of investigator sites worldwide by identifying, contacting, pre-screening and referring people who live in the local community but are unknown to a research site. As a result, trial sponsors complete enrollment without incurring the unexpected expense of adding sites or time.
When you can’t afford a delay in patient enrollment…
Only Acurian can deliver the patients you need, when and where you need them.